Latest in: News

First Patient First Visit Achieved in Phase 2b RIV-CARE Trial of BV100

ADVANCE-ID is pleased to share a significant milestone in the Phase 2b RIV-CARE clinical trial, following BioVersys’ announcement on 29 October 2026 of the first patient first visit in the study. RIV-CARE is an open-label Phase …
October 29, 2026

ADVANCE-ID and WHO Successfully Conclude Clinical Trial Workshop 2026

ADVANCE-ID, in collaboration with the World Health Organization (WHO), successfully organised the ADVANCE-ID Clinical Trial Workshop 2026 from 31 August to 2 September 2026 in Singapore. The two-and-a-half-day workshop brought together researchers and international experts to …
September 2, 2026

Now Available: ADVANCEing CLINICAL TRIALS – A Statistical Guide

ADVANCE-ID is pleased to announce the launch of ADVANCEing CLINICAL TRIALS: a statistical guIDe, a free online educational series designed to strengthen researchers’ understanding of statistical principles and methodologies in clinical trial design and analysis. Supported …
August 31, 2026

ADVANCE-ID Celebrates Official Launch as WHO Collaborating Centre, featured in Singapore Media

ADVANCE-ID marked a significant milestone on 31 August 2026 with the official launch of its designation as a World Health Organization (WHO) Collaborating Centre for Clinical Trials, reinforcing its commitment to strengthening clinical research capacity and …
August 31, 2026

Landmark ACORN-HAI Study Published in The Lancet Infectious Diseases

ADVANCE-ID celebrates the publication of its first study, the ACORN-HAI (A Clinically-Oriented Antimicrobial Resistance Surveillance Network – Healthcare-Associated Infections) study, in The Lancet Infectious Diseases on 21 August 2026. This multicentre prospective cohort study enrolled more …
August 21, 2026

Leadership Transition at ADVANCE-ID: Appointment of Dr Mo Yin as Director

We are pleased to announce that Dr Mo Yin has been appointed as the Director of ADVANCE-ID, with effect from 1 July 2026. An Infectious Diseases physician and clinician-scientist, Dr Mo Yin has served as Deputy …
July 1, 2026

ADVANCE-ID at ESCMID Global 2026

Our ADVANCE-ID team had a wonderful time at ESCMID Global 2026, where we shared our latest research and connected with colleagues from around the world. Throughout the congress, our researchers presented work spanning antimicrobial resistance (AMR), …
April 21, 2026

RECAP: REACH Asia – Responsive Engagement for Advancing Community and Health Research in Asia

Thank you for your interest in the REACH Asia Forum on Community Engagement! The recordings below feature our Expert Talks, with speakers sharing perspectives from across the region on strengthening community engagement and participation in health …
December 16, 2025

CARB-X releases Updated Eligibility Criteria for 2025 Funding Round targeting Global Infectious Disease Threats

Seeking therapeutics for infections caused by Gram-negative pathogens and diagnostics for Salmonella Typhi (BOSTON: November 19, 2025) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today updated eligibility criteria to support its second call of the …
November 19, 2025

REACH Asia – Responsive Engagement for Advancing Community and Health Research in Asia

Join us on 8–9 Dec 2025 for the REACH Asia Forum on Community Engagement! Hear from experts and community leaders across the region on strengthening community engagement and participation in health research.Register at 🔗 https://ad-id.co/reach2025
November 17, 2025
Logo-Lockup

Copyright © ADVANCE-ID. All rights reserved.

ADVANCE-ID
Saw Swee Hock School of Public Health
National University of Singapore

Tahir Foundation Building
National University of Singapore
12 Science Drive 2, #10-01, Singapore 117549
+65 6516 4988